Welcome, Guest. Please login or register.
April 01, 2020, 05:02:17 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 54820
  • Total Topics: 4726
  • Online Today: 79
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 36
Total: 36

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Experimental Hepatitis B Drug, JNJ-6369, Shows Promise in Early Trial  (Read 1302 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 703
    • Hep Mag
An early ongoing study of an experimental treatment for hepatitis B virus (HBV), JNJ-6379, has highlighted the promise of the agent, MedPage Today reports. Researchers have already begun studying it in a more advanced trial.

Presenting their findings at the 52nd International Liver Congress in Paris, researchers conducted a Phase Ib study of the effects of JNJ-6379 on HBeAg-positive or HBeAG-negative people with chronic HBV who had a viral load greater than 2,000 and an ALT liver enzyme level no greater than 2.5 times that of their AST liver enzyme level.

Read more...
https://www.hepmag.com/article/experimental-hepatitis-b-drug-jnj6369-shows-promise-early-trial

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.